Theriva Biologics Announced New Clinical Data From Phase 1 Investigator-sponsored Study With Institut Catala d'Oncologia Evaluating VCN-01 In Combination With Durvalumab
Portfolio Pulse from Benzinga Newsdesk
Theriva Biologics presented new clinical data from a Phase 1 study evaluating VCN-01 in combination with Durvalumab at the European Society for Medical Oncology (ESMO) Congress. The results validate VCN-01's unique mechanism of action for devastating cancers with high unmet need.
October 23, 2023 | 11:12 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Theriva Biologics, potentially linked to TOVX, announced positive results from a Phase 1 study of VCN-01, which could impact TOVX's stock positively.
The positive results from the Phase 1 study of VCN-01, a drug developed by Theriva Biologics, could potentially impact TOVX's stock positively if there is a connection between the two companies. The promising results could attract investor interest and drive up the stock price.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50